Drugs / Terbium 161
last change Mar 2026 re-read 3 minutes ago

Terbium 161

also known as Tb-161
Developed for
neuroendocrine neoplasm
Investigated by
Tata Memorial Hospital

Trials 1

20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07404176 Mar 2026 → Feb 2028 expected neuroendocrine neoplasm Tata Memorial Hospital Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2025-09-30 Affibody Results Affibody Announces Broad Scientific Progress at EANM 2025 affibody.se ↗
favorable preclinical biodistribution of a HER2-targeting Affibody® molecule labeled with the novel radionuclide Terbium-161.
2024-02-28 Radiopharm Theranostics, Ltd Results Pilot Study Validates RAD Terbium-161 Radiotherapeutics radiopharmtheranostics.com ↗
The study demonstrated that 161Tb-PSMA-617 delivers markedly higher tumor-absorbed doses compared to 177Lu-PSMA-617, whereas the absorbed doses of the relevant organs at risk were only slightly higher.

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Terbium-161 “While Lu-177 as a radioisotope is safe and indigenously produced by BARC, the recent global shortage of this isotope has led to development of Terbium-161 (Tb-161).” NCT07404176 ↗
1

NCT07404176 ↗

Known as Tb-161 “While Lu-177 as a radioisotope is safe and indigenously produced by BARC, the recent global shortage of this isotope has led to development of Terbium-161 (Tb-161).” NCT07404176 ↗